Mechanism and Function of ISG15
ISG15的机制和功能
基本信息
- 批准号:10297639
- 负责人:
- 金额:$ 46.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-05-01 至 2026-05-31
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVAntiviral AgentsAreaBiochemicalBiologicalCell Surface ReceptorsCellsCommunicable DiseasesCoronavirusCytotoxic T-LymphocytesDevelopmentDirected Molecular EvolutionDiseaseEnzymesEventExtracellular SpaceFamilyGTP-Binding Protein alpha Subunits, GsGenetic TranscriptionGoalsHomologous GeneHumanISG15 geneImmuneInfectionInnate Immune ResponseIntegrinsInterferon Type IInterferon Type IIInterferonsInterleukin-10Interleukin-6InterventionLeadLigaseLysineMediatingMolecularMusMycobacterium InfectionsMycobacterium tuberculosisPatientsPlayPrincipal InvestigatorProcessProteinsProteomicsRoleSignal PathwaySignal TransductionSignaling ProteinSiteStructureT-LymphocyteUbiquitinUbiquitin Like ProteinsVariantVesicleViralViral ProteinsVirusantimicrobialbetacoronaviruscell typecytokineextracellulargene producthuman pathogenimprovedinsightmicrobialnovelpathogenpathogenic microbepathogenic virusprogramsprotein functionresponse
项目摘要
SUMMARY
Human ISG15 is a ubiquitin-like protein (Ubl) that functions in innate immune responses, and it is
remarkable for possessing three distinct biochemical activities. As a ubiquitin-like modifier it is conjugated to
hundreds of cellular and viral proteins. The E1, E2, E3, and de-conjugating enzymes for ISG15 (Ube1L/Uba7,
UbcH8/Ube2L6, Herc5, and Usp18, respectively), are, like ISG15, induced at the transcriptional level by Type I
interferon (IFN-α/β) signaling. A second function of ISG15 is as an extracellular signaling protein. ISG15 is
released into the extracellular space from many cell types and signals to Natural Killer and T cells to secrete
IFN-γ, which plays a major role in the response to pathogen infections. The cell surface receptor for
extracellular SG15 is LFA-1, an immune cell-specific integrin. A third function of human ISG15 is that it
negatively regulates Type I IFN signaling, as revealed by the Type I interferonopathy that occurs in some
ISG15-deficient patients; this function of human ISG15 is not shared with mouse ISG15. A challenge in the
field is to understand how the activities of ISG15 are regulated and temporally controlled and which activities
are most closely associated with responses to specific pathogens, including Mycobacterium tuberculosis and
SARS-CoV-2. To further our understanding of ISG15 in innate immune responses to these and other
pathogens, this proposal will focus on the basis of substrate and lysine selectivity of the Herc5/Herc6 family of
ISG15 ligases, the ISG15-induced signaling pathway downstream of LFA-1 that leads to cytokine secretion,
and the mechanism by which ISG15 released into the extracellular space.
摘要
人类ISG15是一种泛素样蛋白(Ubl),在先天性免疫反应中发挥作用,它是
因具有三种不同的生化活性而引人注目。作为泛素样修饰物,它与
数以百计的细胞和病毒蛋白。ISG15的E1、E2、E3和解偶联酶(Ube1L/Uba7,
UbcH8/Ube2L6、Herc5和Usp18),与ISG15一样,由I型在转录水平上诱导
干扰素(干扰素-α/β)信号传导。ISG15的第二个功能是作为细胞外信号蛋白。ISG15为
从多种细胞类型释放到细胞外空间,并向自然杀伤细胞和T细胞分泌信号
干扰素-γ,在病原体感染的应答中发挥重要作用。细胞表面受体
细胞外SG15是一种免疫细胞特异性整合素LFA-1。人类ISG15的第三个功能是它
负向调节I型干扰素信号,如某些患者出现的I型干扰素病所揭示的那样
ISG15缺乏的患者;人ISG15的这一功能与小鼠ISG15不同。世界上的一个挑战
实地了解ISG15的活动是如何管理和临时控制的,以及哪些活动
与对特定病原体的反应最密切相关,包括结核分枝杆菌和
SARS-CoV-2。为了加深我们对ISG15先天免疫反应的理解
病原体,这项建议将集中在Herc5/Herc6家族的底物和赖氨酸选择性的基础上
ISG15连接酶,ISG15诱导的LFA-1下游的信号通路,导致细胞因子的分泌,
以及ISG15释放到细胞外空间的机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JON HUIBREGTSE其他文献
JON HUIBREGTSE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JON HUIBREGTSE', 18)}}的其他基金
FASEB SRC on Ubiquitin and Cellular Regulation
FASEB SRC 关于泛素和细胞调节
- 批准号:
8317865 - 财政年份:2012
- 资助金额:
$ 46.43万 - 项目类别:
SPECIFICITY OF UBIQUITINATION--THE HPV E6/E6 AP PARADIGM
泛素化的特异性——HPV E6/E6 AP 范式
- 批准号:
6361396 - 财政年份:1996
- 资助金额:
$ 46.43万 - 项目类别:
Specificity of Ubiquitination: the HPVE6/E6AP Paradigm
泛素化的特异性:HPVE6/E6AP 范式
- 批准号:
6541407 - 财政年份:1996
- 资助金额:
$ 46.43万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 46.43万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 46.43万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 46.43万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 46.43万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 46.43万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 46.43万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 46.43万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 46.43万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 46.43万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 46.43万 - 项目类别: